Incretin analogs as GLP-1, GIP and glucagon receptor triple agonists and uses thereof

TW202633679APending Publication Date: 2026-08-16SUZHOU SPRING SEA BIO PHARM CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: TW114137542
Authority / Receiving Office: TW · TW
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2025-08-08
Filing Date: 2025-09-30
Publication Date: 2026-08-16

Application Information

Patent Timeline

08 Aug 2025

Priority

30 Sep 2025

Application

TW114137542

16 Aug 2026

Publication

TW202633679A

IPC: A61K38/26; A61K38/28; A61P3/00; A61P9/00; A61P19/00; C07K14/605; C07K14/62

Inventors: 赵祖春; 陈刚

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The current disclosure relates to incretin analog compounds that are GLP-1 / GIP / GCG receptor triple agonists and their medical use in the treatment and / or prevention of a disease such as dyslipidemia, fatty liver disease, metabolic syndrome, MASH, obesity and T2DM.

Need to check novelty before this filing date? Find Prior Art